HOME >> BIOLOGY >> NEWS
Wistar Scientists Define Mechanism Of Action Used By Potential Magic Bullet In Cancer Treatment

Farnesyltransferase inhibitors (FTIs) are a relatively new class of nontoxic chemotherapeutic drugs that have an ability to target mutated oncogenes while bypassing normal cells; i.e., they may be the long sought-after magic bullet in cancer treatment.

In pre-clinical studies, FTIs have proven to control the growth of cancer cells and promote tumor regression. Little has been known, however, about how and why they work.

From their recent studies of FTIs, Wistar scientist, George Prendergast, Ph.D., and his Wistar research team made some surprising discoveries about their mechanism of action. Their findings appear today in the March issue of the scientific journal, Molecular and Cellular Biology.

The Wistar scientists had expected FTIs to interfere in some way with the activity of RAS, a cancer protein that tells cells when to start and stop dividing. Instead, they found that FTIs act in large part by affecting RHO, a class of proteins that regulate cell shape, survival and motility. Since RHO levels are elevated in many metastatic tumors, scientists have suspected for some time that RHO and cancer are in some way related. They had not known, however, if their relationship was causative or correlative.

One significant and unexpected finding of the study was that FTIs activate features of RHO by stimulating the production of an isoform with altered properties in the cell. In this way, FTIs make it possible for RHO to perform activities it could not previously perform.

An understanding of RHO alteration as the tumor principle targeted by FTIs will make it possible to make FTIs more effective, avoid drug resistance problems, and design other types of nontoxic antitumor drugs that target the same principle.


'"/>

Contact: Diana Cutshall
dcutshall@wistar.upenn.edu
215-898-3716
The Wistar Institute
17-Feb-1999


Page: 1

Related biology news :

1. Wistar-discovered antibody will help diagnose appendicitis
2. 2004 Wistar Institute Science Journalism Award winners announced
3. Call for Entries: The 2004 Wistar Institute Science Journalism Award
4. Wistar-developed antibody shows promise against brain tumors in Drexel trial
5. Wistar study offers new support for a histone code theory of gene regulation
6. Regeneration in the mammalian heart demonstrated by Wistar researchers
7. Wistar scientists add difficult-to-sequence stretches to human genome data
8. Wistar scientist receives award from National Cancer Institute
9. Director of Emory Vaccine Center to give Wistar Institutes 1999 Tadeusz J. Wiktor Memorial lecture
10. Wistar scientists find striking similarities between bacterial virus and human adenovirus
11. Wistar Institute scientists find key piece in gene regulation puzzle

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... ... July 08, 2020 , ... ... and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, July 22, 2020 • 1:30 ... study, but what is the most effective way to complete one? Will the ...
(Date:7/1/2020)... ... 2020 , ... Catalent, a global leader in clinical supply ... facility in Minakuchi, located in the Shiga prefecture of Japan. , Operating in ... new 60,000-square-foot facility will provide customers with flexible clinical supply solutions, serving both ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... development services, today announced that the company has received ISO9001:2015 certification for ... diagnostics, and research industries. The decision to pursue ISO9001 accreditation demonstrates Kemp’s ...
Breaking Biology News(10 mins):
(Date:8/31/2020)... ... August 29, 2020 , ... ... manufacturing capability in Wuxi, China. The new plant operation will provide the local ... advanced technology. , “This facility will improve the flexibility of our offerings ...
(Date:8/15/2020)... ... August 13, 2020 , ... Inc. magazine ... the most prestigious ranking of the nation’s fastest-growing private companies. The list represents ... dynamic segment—its independent small businesses. Intuit, Zappos, Under Armour, Microsoft, Patagonia, and many ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... firm, is making available for free its new white paper – Simulated ... simulation testing into today’s biologics licensing application (BLA). In response, Modality Solutions ...
(Date:8/7/2020)... ... August 06, 2020 , ... ... industries, announces it has closed on the purchase of greenfield for a new, ... TX and includes over 21 acres in the initial acquisition, with an option ...
Breaking Biology Technology:
Cached News: